These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29936129)

  • 1. Evaluation of the "Quadrella" at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy.
    Coquet JB; Delage F; Fourcade A; Callerot P; Goasduff G; Boussion N; Rousseau B; Serey-Eiffel S; Malhaire JP; Pradier O; Schick U; Fournier G; Valeri A
    Brachytherapy; 2018; 17(5):782-787. PubMed ID: 29936129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on the Quadrella index assessing oncological and functional results after prostate brachytherapy: A 6-year analysis.
    Tremblay G; Nguyen TA; Marolleau J; Malhaire JP; Fourcade A; Boussion N; Goasduff G; Martin E; Dissaux G; Pradier O; Fournier G; Schick U; Valeri A
    J Contemp Brachytherapy; 2023 Apr; 15(2):89-95. PubMed ID: 37215618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erectile function after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erectile function after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
    Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Quadrella: a novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy.
    Tétreault-Laflamme A; Zilli T; Meissner A; Larrivée S; Sylvestre MP; Delouya G; Taussky D
    Radiother Oncol; 2014 Apr; 111(1):110-3. PubMed ID: 24560751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Maeda T; Nakashima J; Sugawara A; Ando T; Mizuno R; Nagata H; Miyajima A; Shigematsu N; Oya M
    J Urol; 2013 Mar; 189(3):1014-8. PubMed ID: 23017516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.
    Buckstein M; Carpenter TJ; Stone NN; Stock RG
    Urology; 2013 Feb; 81(2):364-8. PubMed ID: 23374803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
    Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erectile dysfunction evaluation after brachytherapy for low risk prostate adenocarcinoma: prospective study of patients with a baseline IIEF5>16].
    Delage F; Perrouin-Verbe MA; Le Fur E; Papin G; Thoulouzan M; Malhaire JP; Pradier O; Fournier G; Valéri A
    Prog Urol; 2015 Feb; 25(2):68-74. PubMed ID: 25497176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
    Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
    BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
    Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity.
    Merrick GS; Butler WM; Wallner K; Galbreath RW; Anderson RL; Kurko BS; Lief JH
    Urology; 2002 Jul; 60(1):104-8. PubMed ID: 12100933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of Baseline Erectile Function in Men Following Radical Prostatectomy for High-Risk Prostate Cancer: A Prospective Analysis Using Validated Measures.
    Sridhar AN; Cathcart PJ; Yap T; Hines J; Nathan S; Briggs TP; Kelly JD; Minhas S
    J Sex Med; 2016 Mar; 13(3):435-43. PubMed ID: 26944466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.
    Stone NN; Stock RG
    Urology; 2007 Feb; 69(2):338-42. PubMed ID: 17320674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer.
    Bazinet A; Zorn KC; Taussky D; Delouya G; Liberman D
    Brachytherapy; 2020; 19(2):222-227. PubMed ID: 31837989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy.
    Keyes M; Pickles T; Crook J; McKenzie M; Cheung A; Spadinger I; LaPointe V; Bachand WF; Morris J
    Brachytherapy; 2015; 14(3):334-41. PubMed ID: 25684438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.